That was 2019 …
The year is coming to an end. Also in 2019, there were many interesting news for MS patients, which I also partly commented on in this blog. In my opinion, nothing really groundbreaking has happened.
Continue readingThe year is coming to an end. Also in 2019, there were many interesting news for MS patients, which I also partly commented on in this blog. In my opinion, nothing really groundbreaking has happened.
Continue readingAt the end of September, the 90th Annual Meeting of the German Society of Neurology (DGN) took place in Leipzig. The DGN congress is the most important and largest conference for German-speaking neurologists, where current
Continue readingOn August 25, 2017, the European Medicines Commission EMA approved the active ingredient Cladribin under the trade name MAVENCLAD® for the treatment of relapsing multiple sclerosis (MS) in patients with high disease activity.
Continue readingPresentations of clinical trials for new MS drugs take up a large space at the AAN. It must be said somewhat restrictively that real news is rare at this point. Essentially, evaluations of subgroup analyses
Continue readingUnsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.